Immunic, Inc. (IMUX) stock
IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.52+0.19 (+2.59%)
Close on Nov 18, 2026Market cap $102.61MP/E –Yield 0.00%
Immunic net income
Net income is the profit left for shareholders after every expense, interest and tax.
Immunic's net income for the twelve months ending Jun 30, 2026 was -$111.57M. For fiscal 2025 it was -$97.17M. The highest annual figure on record is -$6.70M in fiscal 2012.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$97.17M | – |
| FY2024 | Dec 31, 2024 | -$100.51M | – |
| FY2023 | Dec 31, 2023 | -$93.61M | – |
| FY2022 | Dec 31, 2022 | -$120.41M | – |
| FY2021 | Dec 31, 2021 | -$92.95M | – |
| FY2020 | Dec 31, 2020 | -$44.02M | – |
| FY2019 | Dec 31, 2019 | -$34.93M | – |
| FY2018 | Dec 31, 2018 | -$11.54M | – |
| FY2017 | Dec 31, 2017 | -$52.08M | – |
| FY2016 | Dec 31, 2016 | -$40.97M | – |
| FY2015 | Dec 31, 2015 | -$52.02M | – |
| FY2014 | Dec 31, 2014 | -$47.67M | – |
| FY2013 | Dec 31, 2013 | -$32.72M | – |
| FY2012 | Dec 31, 2012 | -$6.70M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$34.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -$32.59M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.30M | – |
| Q3 FY2025 | Sep 30, 2025 | -$25.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.82M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.47M | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.37M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.58M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.57M | – |
| Q3 FY2023 | Sep 30, 2023 | -$22.77M | – |
| Q2 FY2023 | Jun 30, 2023 | -$24.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.27M | – |
| Q4 FY2022 | Dec 31, 2022 | -$56.47M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.22M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.90M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.19M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.29M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.93M | – |
| Q1 FY2021 | Mar 31, 2021 | -$34.53M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.16M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.91M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.46M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.49M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.69M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.22M | – |
| Q2 FY2019 | Jun 30, 2019 | -$14.71M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.31M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.81M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.80M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.67M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.26M | – |
| Q4 FY2017 | Dec 31, 2017 | -$14.59M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.48M | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.41M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.60M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.73M | – |
| Q3 FY2016 | Sep 30, 2016 | -$10.18M | – |
See a number that looks wrong?